|
[1] KAPRAL C, MHLBERGER A, WEWALKA F, et al. Quality assessment of endoscopic retrograde cholangiopancreatography:Results of a running nationwide Austrian benchmarking project after 5years of implementation[J]. Eur J Gastroenterol Hepatol, 2012, 24 (12) :1447-1454.
|
|
[2] HANNA MS, PORTAL AJ, DHANDA AD, et al. UK wide survey on the prevention of post-ERCP pancreatitis[J]. Frontline Gastroenterol, 2014, 5 (2) :103-110.
|
|
[3] Chinese Society of Digestive Endoscopy, Chinese Medical Association Pancreatic Disease Committee of Chinese Medical Doctor Association.Expert consensus on pharmacological prevention of pancreatitis after endoscopic retrograde cholangiopancreatography (2015, Shanghai) [J]. J Clin Hepatol, 2016, 32 (5) :830-834. (in Chinese) 中华医学会消化内镜学分会, 中国医师协会胰腺病专业委员会.内镜下逆行胰胆管造影术后胰腺炎药物预防专家共识意见 (2015年, 上海) [J].临床肝胆病杂志, 2016, 32 (5) :830-834.
|
|
[4] COTTON PB, LEHMAN G, VENNES J, et al. Endoscopic sphincterotomy complications and their management:An attempt at consensus[J].Gastrointest Endosc, 1991, 37 (3) :383-393.
|
|
[5] Professional Committee of Pancreatic Disease, Chinese Medical Doctor Association. Chinese consensus on the multidisciplinary treatment (MDT) of acute pancreatitis[J]. J Clin Hepatol, 2015, 31 (11) :1770-1775. (in Chinese) 中国医师学会胰腺病学专业委员会.中国急性胰腺炎多学科诊治共识意见[J].临床肝胆病杂志, 2015, 31 (11) :1770-1775.
|
|
[6] ERCP Group, Chinese Society of Digestive Endoscopology, Chinese Medical Association. Guidelines for the diagnostic and therapeutic ERCP (2010 version) [J]. China Contin Med Educ, 2010, 2 (6) :1-20. (in Chinese) 中华医学会消化内镜分会ERCP学组.内镜下逆行胆胰管造影术 (ERCP) 诊治指南 (2010版) [J].中国继续医学教育, 2010, 2 (6) :1-20.
|
|
[7] ANDRIULLI A, LOPERFIDO S, NAPOLITANO G, et al. Incidence rates of post-ERCP complications:A systematic survey of prospective studies[J]. Am J Gastroenterol, 2007, 102 (8) :1781-1788.
|
|
[8] MASCI E, MARIANI A, CURIONI S, et al. Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography:A meta-analysis[J]. Endoscopy, 2003, 35 (10) :830-834.
|
|
[9] TALUKDAR R. Complications of ERCP[J]. Best Pract Res Clin Gastroenterol, 2016, 30 (5) :793-805.
|
|
[10] KOCHAR B, AKSHINTALA VS, AFGHANI E, et al. Incidence, severity, and mortality of post-ERCP pancreatitis:A systematic review by using randomized, controlled trials[J]. Gastrointest Endosc, 2015, 81 (1) :143-149. e9.
|
|
[11] BANKS PA, BOLLEN TL, DERVENIS C, et al. Classification of acute pancreatitis—2012:Revision of the Atlanta classification and definitions by international consensus[J]. Gut, 2013, 62 (1) :102-111.
|
|
[12] HE QB, XU T, WANG J, et al. Risk factors for post-ERCP pancreatitis and hyperamylasemia:A retrospective single-center study[J]. J Dig Dis, 2015, 16 (8) :471-478.
|
|
[13] INAMDAR S, BERZIN TM, SEJPAL DV, et al. Pregnancy is a Risk factor for pancreatitis after endoscopic retrograde cholangiopancreatography in a national cohort study[J]. Clin Gastroenterol Hepatol, 2016, 14 (1) :107-114.
|
|
[14] KOKSAL AR, BOGA S, ALKIM H, et al. Insulin resistance as a novel risk factor for post-ercp pancreatitis:A pilot study[J]. Dig Dis Sci, 2016, 61 (8) :2397-2405.
|
|
[15] ZHAO ZH, HU LH, REN HB, et al. Incidence and risk factors for post-ERCP pancreatitis in chronic pancreatitis[J]. Gastrointest Endosc, 2017, 86 (3) :519-524. e1.
|
|
[16] RUSTAGI T, JAMIDAR PA. Endoscopic retrograde cholangiopancreatography-related adverse events:General overview[J]. Gastrointest Endosc Clin N Am, 2015, 25 (1) :97-106.
|
|
[17] FREEMAN ML, NELSON DB, SHERMAN S, et al. Complications of endoscopic biliary sphincterotomy[J]. N Engl J Med, 1996, 335 (13) :909-918.
|
|
[18] MASCI E, TOTI G, MARIANI A, et al. Complications of diagnostic and therapeutic ERCP:A prospective multicenter study[J]. Am J Gastroenterol, 2001, 96 (2) :417-423.
|
|
[19] ASGE Standards of Practice Committee, KHASHAB MA, CHITHADI KV, et al. Antibiotic prophylaxis for GI endoscopy[J]. Gastrointest Endosc, 2015, 81 (1) :81-89.
|
|
[20] COLTON JB, CURRAN CC. Quality indicators, including complications, of ERCP in a community setting:A prospective study[J]. Gastrointest Endosc, 2009, 70 (3) :457-467.
|
|
[21] ISMAIL S, KYLNPL, MUSTONEN H, et al. Risk factors for complications of ERCP in primary sclerosing cholangitis[J]. Endoscopy, 2012, 44 (12) :1133-1138.
|
|
[22] CHEN M, WANG L, WANG Y, et al. Risk factor analysis of post-ERCP cholangitis:A single-center experience[J]. Hepatobiliary Pancreat Dis Int, 2018, 17 (1) :55-58.
|
|
[23] COTTON PB, GARROW DA, GALLAGHER J, et al. Risk factors for complications after ERCP:A multivariate analysis of 11, 497procedures over 12 years[J]. Gastrointest Endosc, 2009, 70 (1) :80-88.
|
|
[24] MACHADO NO. Management of duodenal perforation post-endoscopic retrograde cholangiopancreatography. When and whom to operate and what factors determine the outcome? A review article[J]. JOP, 2012, 13 (1) :18-25.
|
|
[25] AVGERINOS DV, LLAGUNA OH, LO AY, et al. Management of endoscopic retrograde cholangiopancreatography:Related duodenal perforations[J]. Surg Endosc, 2009, 23 (4) :833-838.
|
|
[26] MORGAN KA, FONTENOT BB, RUDDY JM, et al. Endoscopic retrograde cholangiopancreatography gut perforations:when to wait!When to operate![J]. Am J Surg, 2009, 75 (6) :477-483.
|
|
[27] ENNS R, ELOUBEIDI MA, MERGENER K, et al. ERCP-related perforations:Risk factors and management[J]. Endoscopy, 2002, 34 (4) :293-298.
|
|
[28] KUMBHARI V, SINHA A, REDDY A, et al. Algorithm for the management of ERCP-related perforations[J]. Gastrointest Endosc, 2016, 83 (5) :934-943.
|
|
[29] WILLIAMS EJ, TAYLOR S, FAIRCLOUGH P, et al. Risk factors for complication following ERCP; Results of a large-scale, prospective multicenter study[J]. Endoscopy, 2007, 39 (9) :793-801.
|
|
[30] DUMONCEAU JM, ANDRIULLI A, ELMUNZER BJ, et al. Prophylaxis of post-ERCP pancreatitis:European Society of Gastrointestinal Endoscopy (ESGE) Guideline-updated June 2014[J]. Endoscopy, 2014, 46 (9) :799-815.
|
|
[31] WONG LL, TSAI HH. Prevention of post-ERCP pancreatitis[J].World J Gastrointest Pathophysiol, 2014, 5 (1) :1-10.
|
|
[32] PATAI, SOLYMOSI N, MOHCSI L, et al. Indomethacin and diclofenac in the prevention of post-ERCP pancreatitis:A systematic review and meta-analysis of prospective controlled trials[J].Gastrointest Endosc, 2017, 85 (6) :1144-1156. e1.
|
|
[33] ANDRADE-DVILA VF, CHVEZ-TOSTADO M, DVALOSCOBIN C, et al. Rectal indomethacin versus placebo to reduce the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography:Results of a controlled clinical trial[J]. BMC Gastroenterol, 2015, 15 (1) :85.
|
|
[34] KATO K, SHIBA M, KAKIYA Y, et al. Celecoxib oral administration for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis:A randomized prospective trial[J]. Pancreas, 2017, 46 (7) :880-886.
|
|
[35] LEE TY, CHOI JS, OH HC, et al. Oral udenafil and aceclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients:A randomized multicenter study[J]. Korean J Intern Med, 2015, 30 (5) :602-609.
|
|
[36] LEVENICK JM, GORDON SR, FADDEN LL, et al. Rectal indomethacin does not prevent post-ercp pancreatitis in consecutive patients[J].Gastroenterology, 2016, 150 (4) :911-917.
|
|
[37] LI L, HAN Z, YUAN H, et al. Nonsteroidal anti-inflammatory drugs reduce the incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis:A meta-analysis[J]. J Hepatobiliary Pancreat Sci, 2017, 24 (9) :520-529.
|
|
[38] PUIG I, CALVET X, BAYLINA M, et al. How and when should NSAIDs be used for preventing post-ERCP pancreatitis? A systematic review and meta-analysis[J]. PLo S One, 2014, 9 (3) :e92922.
|
|
[39] YANG C, ZHAO Y, LI W, et al. Rectal nonsteroidal anti-inflammatory drugs administration is effective for the prevention of postERCP pancreatitis:An updated meta-analysis of randomized controlled trials[J]. Pancreatology, 2017, 17 (5) :681-688.
|
|
[40] WAN J, REN Y, ZHU Z, et al. How to select patients and timing for rectal indomethacin to prevent post-ERCP pancreatitis:A systematic review and meta-analysis[J]. BMC Gastroenterol, 2017, 17 (1) :43.
|
|
[41] LUO H, ZHAO L, LEUNG J, et al. Routine pre-procedural rectal indometacin versus selective post-procedural rectal indometacin to prevent pancreatitis in patients undergoing endoscopic retrograde cholangiopancreatography:A multicentre, single-blinded, randomised controlled trial[J]. Lancet, 2016, 387 (10035) :2293-2301.
|
|
[42] RAI U, THRIMAWITHANA TR, VALERY C, et al. Therapeutic uses of somatostatin and its analogues:Current view and potential applications[J]. Pharmacol Ther, 2015, 152:98-110.
|
|
[43] BAI Y, REN X, ZHANG XF, et al. Prophylactic somatostatin can reduce incidence of post-ERCP pancreatitis:Multicenter randomized controlled trial[J]. Endoscopy, 2015, 47 (5) :415-420.
|
|
[44] QIN X, LEI WS, XING ZX, et al. Prophylactic effect of somatostatin in preventing Post-ERCP pancreatitis:An updated meta-analysis[J]. Saudi J Gastroenterol, 2015, 21 (6) :372-378.
|
|
[45] WANG G, XIAO G, XU L, et al. Effect of somatostatin on prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis and hyperamylasemia:A systematic review and meta-analysis[J]. Pancreatology, 2018, 18 (4) :370-378.
|
|
[46] LI ZS, PAN X, ZHANG WJ, et al. Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia:A multicenter, placebo-controlled, randomized clinical trial[J]. Am J Gastroenterol, 2007, 102 (1) :46-51.
|
|
[47] ZHANG Y, CHEN QB, GAO ZY, et al. Meta-analysis:Octreotide prevents post-ERCP pancreatitis, but only at sufficient doses[J]. Aliment Pharmacol Ther, 2009, 29 (11) :1155-1164.
|
|
[48] OMATA F, DESHPANDE G, TOKUDA Y, et al. Meta-analysis:Somatostatin or its long-acting analogue, octreotide, for prophylaxis against post-ERCP pancreatitis[J]. J Gastroenterol, 2010, 45 (8) :885-895.
|
|
[49] YUHARA H, OGAWA M, KAWAGUCHI Y, et al. Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis:Protease inhibitors and NSAIDs in a meta-analysis[J]. J Gastroenterol, 2014, 49 (3) :388-399.
|
|
[50] ZHANG ZF, YANG N, ZHAO G, et al. Preventive effect of ulinastatin and gabexate mesylate on post-endoscopic retrograde cholangiopancreatography pancreatitis[J]. Chin Med J (Engl) , 2010, 123 (18) :2600-2606.
|
|
[51] ZHU K, WANG JP, SU JG. Prophylactic ulinastatin administration for preventing post-endoscopic retrograde cholangiopancreatography pancreatitis:A meta-analysis[J]. Exp Ther Med, 2017, 14 (4) :3036-3056.
|
|
[52] KIM SJ, KANG DH, KIM HW, et al. A randomized comparative study of 24-and 6-hour infusion of nafamostat mesilate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis:A prospective randomized comparison trial[J]. Pancreas, 2016, 45 (8) :1179-1183.
|
|
[53] STARITZ M, PORALLA T, EWE K, et al. Effect of glyceryl trinitrate on the sphincter of Oddi motility and baseline pressure[J].Gut, 1985, 26 (2) :194-197.
|
|
[54] BRANDSTTTER G, SCHINZEL S, WURZER H. Influence of spasmolytic analgesics on motility of sphincter of Oddi[J]. Dig Dis Sci, 1996, 41 (9) :1814-1818.
|
|
[55] BAI Y, XU C, YANG X, et al. Glyceryl trinitrate for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography:A meta-analysis of randomized, double-blind, placebo-controlled trials[J]. Endoscopy, 2009, 41 (8) :690-695.
|
|
[56] KATSINELOS P, LAZARAKI G, CHATZIMAVROUDIS G, et al.Impact of nitroglycerin and glucagon administration on selective common bile duct cannulation and prevention of post-ERCP pancreatitis[J]. Scand J Gastroenterol, 2017, 52 (1) :50-55.
|
|
[57] PARK CH, PAIK WH, PARK ET, et al. Aggressive intravenous hydration with lactated Ringer’s solution for prevention of postERCP pancreatitis:A prospective randomized multicenter clinical trial[J]. Endoscopy, 2018, 50 (4) :378-385.
|
|
[58] ZHANG ZF, DUAN ZJ, WANG LX, et al. Aggressive hydration with lactated ringer solution in prevention of postendoscopic retrograde cholangiopancreatography pncreatitis:A Meta-analysis of Randomized Controlled Trials[J]. J Clin Gastroenterol, 2017, 51 (3) :e17-e26.
|
|
[59] MOK SRS, HO HC, SHAH P, et al. Lactated Ringer's solution in combination with rectal indomethacin for prevention of post-ERCP pancreatitis and readmission:A prospective randomized, doubleblinded, placebo-controlled trial[J]. Gastrointest Endosc, 2017, 85 (5) :1005-1013.
|
|
[60] WU D, WAN J, XIA L, et al. The efficiency of aggressive hydration with lactated ringer solution for the prevention of Post-ERCP pancreatitis:A systematic review and meta-analysis[J]. J Clin Gastroenterol, 2017, 51 (8) :e68-e76.
|
|
[61] MATSUSHITA M, TAKAKUWA H, SHIMENO N, et al. Epinephrine sprayed on the papilla for prevention of post-ERCP pancreatitis[J]. J Gastroenterol, 2009, 44 (1) :71-75.
|
|
[62] XU LH, QIAN JB, GU LG, et al. Prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis by epinephrine sprayed on the papilla[J]. J Gastroenterol Hepatol, 2011, 26 (7) :1139-1144.
|
|
[63] BAI Y, GAO J, SHI X, et al. Prophylactic corticosteroids do not prevent post-ERCP pancreatitis:A meta-analysis of randomized controlled trials[J]. Pancreatology, 2008, 8 (4-5) :504-509.
|
|
[64] DUMOT JA, CONWELL DL, ZUCCARO G JR, et al. A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis[J]. Am J Gastroenterol, 2001, 96 (7) :2098-2102.
|
|
[65] LI S, CAO G, CHEN X, et al. Low-dose heparin in the prevention of post endoscopic retrograde cholangiopancreatography pancreatitis:A systematic review and meta-analysis[J]. Eur J Gastroenterol Hepatol, 2012, 24 (5) :477-481.
|
|
[66] BAI Y, GAO J, ZHANG W, et al. Meta-analysis:Allopurinol in the prevention of postendoscopic retrograde cholangiopancreatography pancreatitis[J]. Aliment Pharmacol Ther, 2008, 28 (5) :557-564.
|
|
[67] KATSINELOS P, KOUNTOURAS J, PAROUTOGLOU G, et al.Intravenous N-acetylcysteine does not prevent post-ERCP pancreatitis[J]. Gastrointest Endosc, 2005, 62 (1) :105-111.
|
|
[68] LAVY A, KARBAN A, SUISSA A, et al. Natural beta-carotene for the prevention of post-ERCP pancreatitis[J]. Pancreas, 2004, 29 (2) :e45-e50.
|
|
[69] GORELICK A, BARNETT J, CHEY W, et al. Botulinum toxin injection after biliary sphincterotomy[J]. Endoscopy, 2004, 36 (2) :170-173.
|
|
[70] SCHWARTZ JJ, LEW RJ, AHMAD NA, et al. The effect of lidocaine sprayed on the major duodenal papilla on the frequency of post-ERCP pancreatitis[J]. Gastrointest Endosc, 2004, 59 (2) :179-184.
|
|
[71] PRAT F, AMARIS J, DUCOT B, et al. Nifedipine for prevention of post-ERCP pancreatitis:A prospective, double-blind randomized study[J]. Gastrointest Endosc, 2002, 56 (2) :202-208.
|
|
[72] SAND J, NORDBACK I. Prospective randomized trial of the effect of nifedipine on pancreatic irritation after endoscopic retrograde cholangiopancreatography[J]. Digestion, 1993, 54 (2) :105-111.
|
|
[73] KIM NH, KIM HJ, BANG KB. Prospective comparison of prophylactic antibiotic use between intravenous moxifloxacin and ceftriaxone for high-risk patients with post-ERCP cholangitis[J]. Hepatobiliary Pancreat Dis Int, 2017, 16 (5) :512-518.
|
|
[74] MILLWARD SF. ACR appropriateness criteria on treatment of acute nonvariceal gastrointestinal tract bleeding[J]. J Am Coll Radiol, 2008, 5 (4) :550-554.
|
|
[75] DUNNE R, MCCARTHY E, JOYCE E, et al. Post-endoscopic biliary sphincterotomy bleeding:An interventional radiology approach[J]. Acta Radiol, 2013, 54 (10) :1159-1164.
|
|
[76] DAY LW, LIN L, SOMSOUK M. Adverse events in older patients undergoing ERCP:A systematic review and meta-analysis[J].Endosc Int Open, 2014, 2 (1) :e28-e36.
|
|
[77] HAMADA T, YASUNAGA H, NAKAI Y, et al. Bleeding after endoscopic sphincterotomy or papillary balloon dilation among users of antithrombotic agents[J]. Endoscopy, 2015, 47 (11) :997-1004.
|
|
[78] MOK SR, ARIF M, DIEHL DL, et al. Safety and efficacy of minimal biliary sphincterotomy with papillary balloon dilation (m-EBS+EPBD) in patients using clopidogrel or anticoagulation[J]. Endosc Int Open, 2017, 5 (3) :e157-e164.
|
|
[79] CHAN FKL, GOH KL, REDDY N, et al. Management of patients on antithrombotic agents undergoing emergency and elective endoscopy:Joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines[J]. Gut, 2018, 67 (3) :405-417.
|
|
[80] VEITCH AM, VANBIERVLIET G, GERSHLICK AH, et al. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants:British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines[J].Gut, 2016, 65 (3) :374-389.
|
|
[81] ASGE Standards of Practice Committee, ACOSTA RD, ABRAHAM NS, et al. The management of antithrombotic agents for patients undergoing GI endoscopy[J]. Gastrointest Endosc, 2016, 83 (1) :3-16.
|
|
[82] NAVANEETHAN U, NJEI B, ZHU X, et al. Safety of ERCP in patients with liver cirrhosis:A national database study[J]. Endosc Int Open, 2017, 5 (4) :e303-e314.
|
|
[83] LI DM, ZHAO J, ZHAO Q, et al. Safety and efficacy of endoscopic retrograde cholangiopancreatography for common bile duct stones in liver cirrhotic patients[J]. J Huazhong Univ Sci Technolog Med Sci, 2014, 34 (4) :612-615.
|
|
[84] BALDERRAMO D, BORDAS JM, SENDINO O, et al. Complications after ERCP in liver transplant recipients[J]. Gastrointest Endosc, 2011, 74 (2) :285-294.
|
PDF下载 ( 1710 KB)
本文二维码
下载:
